Get the Stockscreener App
1.74
3.57%
0.06
Lineage Cell Therapeutics Inc stock is traded at $1.74, with a volume of 967.37K.
It is up +3.57% in the last 24 hours and down -3.33% over the past month.
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also develops Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy; ReGlyde, a HyStem product in preclinical development as a device for viscosupplementation, and as a platform for intraarticular drug delivery in osteoarthritis; and Premvia, a Hystem Hydrogel product, as well as develop bone grafting products for the orthopedic diseases and injuries. In addition, it markets GeneCards, a human gene database; MalaCards, a human disease database; and Hextend, a plasma volume expander used to treat or prevent hypovolemia, including albumin, generic 6% hetastarch solutions, and crystalloid solutions, as well as undertakes various research programs for vision restoration and Demyelination. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was founded in 1990 and is headquartered in Carlsbad, California.
See More
Previous Close:
$1.68
Open:
$1.66
24h Volume:
967.37K
Relative Volume:
0.51
Market Cap:
$400.77M
Revenue:
$8.95M
Net Income/Loss:
$-21.49M
P/E Ratio:
-14.50
EPS:
-0.12
Net Cash Flow:
$-29.24M
1W Performance:
+1.75%
1M Performance:
-3.33%
6M Performance:
+164.36%
1Y Performance:
+233.27%
1-Day Range:
$1.62
$1.75
1-Week Range:
$1.57
$1.76
52-Week Range:
$0.3651
$2.09
Lineage Cell Therapeutics Inc Stock (LCTX) Company Profile
Name
Lineage Cell Therapeutics Inc
Sector
Industry
Phone
510-871-4188
Address
2173 Salk Avenue, Suite 200, Carlsbad, CA
Compare LCTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LCTX
Lineage Cell Therapeutics Inc
|
1.74 | 386.95M | 8.95M | -21.49M | -29.24M | -0.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Lineage Cell Therapeutics Inc Stock (LCTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-20-24 | Initiated | Craig Hallum | Buy |
| Nov-02-22 | Initiated | Robert W. Baird | Outperform |
| Jun-14-22 | Initiated | B. Riley Securities | Buy |
| Aug-19-21 | Initiated | Noble Capital Markets | Outperform |
| Mar-31-21 | Initiated | Cantor Fitzgerald | Overweight |
Lineage Cell Therapeutics Inc Stock (LCTX) Latest News
How Lineage Cell Therapeutics Inc. stock valuation compares with sector2025 Historical Comparison & Smart Investment Allocation Tips - Newser
What insider trading reveals about Lineage Cell Therapeutics Inc. stockSell Signal & Daily Growth Stock Tips - Newser
Is Lineage Cell Therapeutics Inc. stock a smart buy before Fed meetingJuly 2025 Short Interest & AI Optimized Trading Strategy Guides - Newser
How Lineage Cell Therapeutics Inc. stock performs during market turbulence2025 Top Decliners & Safe Swing Trade Setups - Newser
How currency fluctuations impact Lineage Cell Therapeutics Inc. stockPortfolio Value Summary & Accurate Intraday Trade Tips - Newser
Is Lineage Cell Therapeutics Inc. stock safe for risk averse investorsCEO Change & Daily Stock Trend Reports - Newser
Is Lineage Cell Therapeutics Inc. stock attractive for growth ETFsPortfolio Gains Summary & Free Expert Verified Stock Movement Alerts - Newser
Is Lineage Cell Therapeutics Inc. stock cheap by valuation metricsJuly 2025 Review & Entry Point Confirmation Alerts - Newser
Is Lineage Cell Therapeutics Inc. stock expanding market penetrationMarket Growth Report & Technical Entry and Exit Alerts - Newser
Will Lineage Cell Therapeutics Inc. stock beat international competitionJuly 2025 Action & Precise Swing Trade Entry Alerts - Newser
An analyst sees good growth prospects for Lineage Cell Therapeutics Inc (LCTX) - Setenews
Is Lineage Cell Therapeutics Inc. stock a buy on weaknessTreasury Yields & Long-Term Growth Plans - Newser
Can Lineage Cell Therapeutics Inc. stock weather global recession2025 Winners & Losers & Technical Pattern Based Buy Signals - Newser
Lineage Cell Therapeutics withdraws CIRM grant application, plans resubmission By Investing.com - Investing.com Australia
Lineage Therap Withdraws CIRM Grant Application - TipRanks
Lineage Cell Therapeutics Inc withdrew CIRM grant application filed in June 2025SEC filing - marketscreener.com
Lineage Cell Therapeutics withdraws CIRM grant application, plans resubmission - Investing.com
Lineage Cell Therapeutics Withdraws CIRM Grant Application - TradingView
Lineage Cell Therapeutics (LCTX) pulls CIRM CLIN2 grant application, plans OPC1 resubmission - Stock Titan
What analysts say about Lineage Cell Therapeutics Inc stockLong-Term Investment Plans & Small Capital Portfolio Tips - earlytimes.in
Does Tuni Textile Mills Limited Have Competitive Moats for LongTerm GrowthDividend Yield Trends & Superior Wealth Strategies - earlytimes.in
Can Shri Jagdamba Polymers Limited Deliver Stable Cash Flow in Market DownturnsRisk-Reward Ratio Analysis & Fast Profit Portfolio Plans - earlytimes.in
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Earns Buy Rating from D. Boral Capital - Defense World
Lineage Cell says first OpRegen development milestone under Roche pact achieved - MSN
This trade activity should not be overlooked: Lineage Cell Therapeutics Inc (LCTX) - Setenews
D. Boral Capital Maintains Lineage Cell Therapeutics (LCTX) Buy Recommendation - Nasdaq
Lineage Cell Therapeutics explores future of dry AMD treatment - Traders Union
LCTX: D. Boral Capital Maintains 'Buy' Rating with $2.00 Price T - GuruFocus
HC Wainwright & Co. Maintains Lineage Cell Therapeutics (LCTX) Buy Recommendation - Nasdaq
HC Wainwright & Co. Maintains Buy Rating for LCTX with $9 Target - GuruFocus
Lineage Therap Secures $5M Milestone Payment - TipRanks
Lineage Cell Therapeutics : Achieves First Milestone Under Worldwide Collaboration Agreement with Genentech - MarketScreener
[8-K] Lineage Cell Therapeutics, Inc. Reports Material Event | LCTX SEC FilingForm 8-K - Stock Titan
Lineage Cell Therapeutics Q3 2025 Earnings Preview - MSN
Why Lineage Cell Therapeutics Inc. stock is popular among millennialsTrade Risk Assessment & Daily Risk Controlled Trade Plans - newser.com
Is Lineage Cell Therapeutics Inc. stock a buy before product launches2025 Valuation Update & Long-Term Growth Stock Strategies - newser.com
Will Lineage Cell Therapeutics Inc. stock test record highs in 20252025 Support & Resistance & Risk Managed Investment Strategies - newser.com
Why Lineage Cell Therapeutics Inc. stock could see breakout soon2025 Trading Recap & Technical Entry and Exit Alerts - newser.com
Forecasting Lineage Cell Therapeutics Inc. price range with options dataJuly 2025 Highlights & Low Risk Entry Point Tips - newser.com
How Lineage Cell Therapeutics Inc. stock reacts to oil pricesPortfolio Return Report & Entry and Exit Point Strategies - newser.com
Is Lineage Cell Therapeutics Inc. stock a momentum leader - newser.com
Lineage Cell Therapeutics Inc Stock (LCTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):